<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="styles.css">
    <title>From Scalpel to Genes - Kevin Rugira</title>
    <style>
        body {
            background-color: #faebd0;
            font-family: 'Courier New', Courier, monospace;
            color: #333;
            max-width: 80%;  
            margin: auto;
            padding: 0 40px;   
        }

        .blog-title {
            text-align: center;
            margin: 50px;
            font-size: 36px;
            font-weight: bold;
        }

        img {
            display: block;
            margin: auto;
            max-width: 500px;
            height: auto;
        }

        p {
            margin: 20px;
            text-align: justify;
  }

        .image-description {
            text-align: center;
            font-size: 14px;
            color: #666;
        }

        .times { 
            font-family: 'Courier New', Courier, monospace; 
        }
    </style>
</head>
<body>
  <div class="blog-title">FROM SCALPEL TO GENES: A RESILIENT BATTLE AGAINST BREAST CANCER</div>
    
    <img src="Breast MRI invasive ductal carcinoma_Computer-aided_volumetry_images_pre and post chemo_partial_response_RSNA.jpeg" alt="Breast MRI showing carcinoma pre and post chemotherapy">

    <p class="image-description">
        Sagittal breast MRI showing computer-aided volumetry images of a 31-year-old woman with invasive ductal carcinoma. Pre-chemotherapy(left), Post-chemotherapy(right).
    </p>

    <p class="times">
        In the complex dance of cellular life and death, a devastating enemy lurks within the genetic fabric of millions. This enemy, known by its common name, breast cancer, has waged a silent war against humanity, most particularly against women, that echoes through the annals of history.
    </p>

    <p class="times">
        The story of breast cancer, replete with its heroes and villains, failures and successes, despair, and hope, is as profound as the genetic mutations that foster its insidious existence. In this blog, we trace this narrative not merely as a clinical discourse but as a detailed account, an intimate journey within the cellular universe where each triumph is often tempered by the dark veils of imminent defeats.
    </p>

    <p class="times">
        It's the late 19th century, and the arsenal of medical interventions is yet sparse, characterized by therapies of brutal and barbaric simplicity. The radical mastectomy, as performed by surgeons like William Stewart Halsted, cut into the diseased flesh but took away as much healthy tissue as a cautionary measure against regrowth and metastasis. For the surviving patients, it offered a sense of desperate hope. It was a symbol of resilience against the specter of cancer, but the looming possibility of recurrence remained.
    </p>

    <p class="times">
        As the shadow of radical mastectomy lingered well into the 20th century, the world saw a palpable shift in the treatment of breast cancer following the pioneering discovery of Marie Curie. Radiation therapy, once a conceptual mystery, found its way into the medical toolkit. This marked a liberating period for the afflicted from the harrowing incisions of the scalpel to the subtle power of photons.
    </p>

   <p class="times">
        In the post-war era of the 1940s, another revolutionary chapter in this story unfolded. In the bleak landscape of cancer treatment, a man named Sidney Farber stationed at the Boston Children’s Hospital introduced chemotherapy. It was not a eureka moment akin to Archimedes’ triumphant discovery in his bathtub, rather a grueling journey of trials, errors, and unyielding persistence. Farber’s experiments with antifolates, a type of molecule that interferes with the cell’s ability to divide and multiply, led to the development of a drug that could induce remission in children with leukemia. His work challenged cancer at the molecular core for the first time and brought the world’s attention to the potential of chemicals in taming cancerous cell proliferation.
    </p>

    <p class="times">
        About 80% of breast cancers are estrogen receptor-positive. This predominant form of breast cancer, influenced by the hormone estrogen, has shaped many therapeutic interventions. These interventions target the cellular mechanisms sensitive to hormonal fluctuations, and the strategic administration of hormone-blocking agents has offered significant relief and increased survival rates.
    </p>

    <p class="times">
        While the search for a cure continues, we’ve made significant strides in the realm of personalized medicine. Today’s oncology treatments are characterized by targeted therapies, such as immunotherapy and hormone therapy, which are tailored to the individual’s genetic makeup and the specific cellular environment of their cancer. This era of personalized medicine promises treatments that are not only more effective but also come with fewer side effects, marking a pivotal moment in our ongoing battle against this formidable enemy.
    </p>

    <p class="times">
        Over the next two months, I will be working on a personal project building a drug response predictor tool. This tool aims to predict individual patient responses to Tamoxifen, a commonly used drug in treating estrogen receptor-positive cancers, based on their genomic data.  This tool represents a convergence of precision, data, and technology, aimed at creating a future where breast cancer treatments are highly personalized, and tailored to the individual's unique genetic makeup.
</body>
</html>

